TransMedics Group, Inc. Q3 FY2025 earnings call

• Organ transplantation remains a key focus for policymakers globally. TransMedics is uniquely positioned with OCS technology, NOP clinical and logistical services, and a proprietary transplant digital ecosystem.
• Q3 2025 results: Total revenue ~$143.8M, 32.2% YOY growth; growth across all organ segments. Gross margins ~59%, operating profit ~$23.3M.
• Next-Gen OCS ENHANCE Heart and DENOVO Lung clinical programs: Expecting patient enrollment in Q4 2025, with IDE conditions expected to be satisfied by early 2026.
• International expansion: Plan to launch first OUS NOP program in Italy, with up to 4 hubs established, aiming to launch in first half of 2026. Engaged with other European countries and regions outside Europe.
• Pilot program: Experimenting with double shifting a portion of aircraft fleet by year-end to enhance operational efficiency.
• Long-term initiatives: Progress on OCS Kidney program, Gen 3 OCS platform development, and narrowing down selection for new global headquarters in Somerville, MA.

Total revenue for 3Q 2025 was approximately $143.8 million, representing ~32.2% year-over-year growth. Year-over-year growth was seen across all organ segments: liver up nearly 41%, heart up ~14%, and lung up ~5%. Product revenue for the third quarter was $88 million, up 33% year-over-year, and service revenue was $56 million, up 31% year-over-year. Logistics revenue for 3Q was $27.2 million, representing approximately 35% year-over-year growth. Overall gross margins for 3Q were approximately 59%, up 2.9% year-over-year. Operating profit was approximately $23.3 million in 3Q, up from $3.9 million in 3Q 2024.

• Narrowed full-year 2025 revenue guidance to $595 million to $605 million, representing ~36% growth YOY compared to 2024.
• Expect operating margins to fluctuate as capital is deployed across initiatives but remain confident in long-term growth.
• Guidance for 2026 to be issued at the next earnings call.

• Forward-looking statements involve risks and uncertainties that could materially differ from actual results, as detailed in Risk Factors of Form 10-Q and subsequent SEC filings.
• Potential impact of OPO decertification on organ transplants, though viewed as a potential opportunity rather than significant risk at this point.
• Challenges in tailoring NOP and logistics services to European geographies with varying clinical and regulatory requirements.

Q: Allen Gong from JPMorgan asked about the trajectory into 4Q and 2026, and international expansion.

A: Waleed Hassanein responded that seasonality in organ transplant is anticipated, 2026 guidance to be issued at next earnings call, and Europe requires tailored approaches with Italy as a first step.

Q: William Plovanic from Canaccord inquired about trial enrollment timing and operating margin guide.

A: Waleed Hassanein said first patients will be enrolled in Q4, and Gerardo Hernandez mentioned more color on European NOP CapEx to come.

Q: Matthew Mardula from William Blair asked about OPO decertification impact and waitlist status.

A: Waleed Hassanein stated no disruption seen from OPO decertification and waitlist is dynamic.

Q: Christopher Pasquale from Nephron Research asked about logistics penetration and NOP Connect impact.

A: Waleed Hassanein clarified tracking tail numbers isn't 100% reflective, and Gerardo Hernandez said no significant change in transportation split.

Q: Joshua Jennings from TD Cowen asked about 2025 guidance increase and donor registrations.

A: Waleed Hassanein and Gerardo Hernandez mentioned confidence in guidance and no major impact on donor registrations.

Q: Suraj Kalia from Oppenheimer & Co. asked about liver share gains and transportation structure.

A: Waleed Hassanein clarified on transportation tracking, and Gerardo Hernandez said no significant change in transportation split.

Q: Patrick Wood from Morgan Stanley asked about double shifting aircraft.

A: Waleed Hassanein explained double shifting aims to maximize fleet efficiency.

Q: Samantha Munoz from Piper Sandler asked about 10,000 transplant target and next-gen trial duration.

A: Waleed Hassanein discussed confidence in reaching 10,000 transplants and trial duration expectations.

Q: David Rescott from Baird asked about trial timing differences and Europe market fragmentation.

A: Waleed Hassanein clarified trial timing and Gerardo Hernandez mentioned margin details to come.

Q: Michael Matson from Needham & Company asked about heart trial design and kidney program.

A: Waleed Hassanein explained heart trial endpoint and kidney program plans.

Q: Daniel Markowitz from Evercore asked about trial contribution and OrganOx acquisition reaction.

A: Waleed Hassanein said trial contribution minimal now, and reacted positively to OrganOx acquisition.

Q: Thomas Stephan from Stifel asked about OCS pressure during market slowdown.

A: Waleed Hassanein discussed market seasonality and TransMedics' market share growth.

Q: Young Li from Jefferies asked about factors in faster trial enrollment.

A: Waleed Hassanein mentioned momentum and excitement driving enrollment but emphasized execution is key.